FOSUN PHARMA (02196) Subsidiary Secures NMPA Green Light for Phase I Trial of Next-Generation Bcl-2 Inhibitor FXS0683

Bulletin Express03-13

Shanghai-listed FOSUN PHARMA (02196) announced that its wholly owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., has obtained approval from China’s National Medical Products Administration (NMPA) to initiate Phase I clinical trials of FXS0683 Tablets for hematological malignancies.

FXS0683 is an orally administered, highly potent and selective next-generation Bcl-2 inhibitor designed to induce apoptosis in malignant blood cells by inhibiting both wild-type and mutant Bcl-2 proteins. The compound is fully developed in-house by the Fosun Pharma group.

To date, the group has invested approximately RMB27.00 million in research and development of FXS0683. According to IQVIA CHPA data, China’s Bcl-2 inhibitor market generated sales of roughly RMB338.00 million in 2025, underscoring the commercial potential of novel entrants in this therapeutic class.

The investigational drug must still progress through the full clinical trial pathway and obtain further regulatory approvals before commercialization. The company cautions that drug development carries inherent uncertainties, including potential termination of trials due to safety or efficacy concerns.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183078618?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 18:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183078618","market":"hk","top_or_hot":-1,"title":"FOSUN PHARMA (02196) Subsidiary Secures NMPA Green Light for Phase I Trial of Next-Generation Bcl-2 Inhibitor FXS0683","media":"Bulletin Express","content":"<p>Shanghai-listed FOSUN PHARMA (02196) announced that its wholly owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., has obtained approval from China’s National Medical Products Administration (NMPA) to initiate Phase I clinical trials of FXS0683 Tablets for hematological malignancies.</p>\n<p>FXS0683 is an orally administered, highly potent and selective next-generation Bcl-2 inhibitor designed to induce apoptosis in malignant blood cells by inhibiting both wild-type and mutant Bcl-2 proteins. The compound is fully developed in-house by the Fosun Pharma group.</p>\n<p>To date, the group has invested approximately RMB27.00 million in research and development of FXS0683. According to IQVIA CHPA data, China’s Bcl-2 inhibitor market generated sales of roughly RMB338.00 million in 2025, underscoring the commercial potential of novel entrants in this therapeutic class.</p>\n<p>The investigational drug must still progress through the full clinical trial pathway and obtain further regulatory approvals before commercialization. The company cautions that drug development carries inherent uncertainties, including potential termination of trials due to safety or efficacy concerns.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA (02196) Subsidiary Secures NMPA Green Light for Phase I Trial of Next-Generation Bcl-2 Inhibitor FXS0683</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA (02196) Subsidiary Secures NMPA Green Light for Phase I Trial of Next-Generation Bcl-2 Inhibitor FXS0683\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-13 18:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai-listed FOSUN PHARMA (02196) announced that its wholly owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., has obtained approval from China’s National Medical Products Administration (NMPA) to initiate Phase I clinical trials of FXS0683 Tablets for hematological malignancies.</p>\n<p>FXS0683 is an orally administered, highly potent and selective next-generation Bcl-2 inhibitor designed to induce apoptosis in malignant blood cells by inhibiting both wild-type and mutant Bcl-2 proteins. The compound is fully developed in-house by the Fosun Pharma group.</p>\n<p>To date, the group has invested approximately RMB27.00 million in research and development of FXS0683. According to IQVIA CHPA data, China’s Bcl-2 inhibitor market generated sales of roughly RMB338.00 million in 2025, underscoring the commercial potential of novel entrants in this therapeutic class.</p>\n<p>The investigational drug must still progress through the full clinical trial pathway and obtain further regulatory approvals before commercialization. The company cautions that drug development carries inherent uncertainties, including potential termination of trials due to safety or efficacy concerns.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1183078618","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183078618","pubTimestamp":1773396094,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai-listed FOSUN PHARMA (02196) announced that its wholly owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., has obtained approval from China’s National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药(02196)子公司下一代Bcl-2抑制剂FXS0683 I期试验获NMPA绿灯","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai-listed FOSUN PHARMA (02196) announced that its wholly owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., has obtained approval from China’s National Medical Products Administration (NMPA) to initiate Phase I clinical trials of FXS0683 Tablets for hematological malignancies.\nFXS0683 is an orally administered, highly potent and selective next-generation Bcl-2 inhibitor designed to induce apoptosis in malignant blood cells by inhibiting both wild-type and mutant Bcl-2 proteins. The compound is fully developed in-house by the Fosun Pharma group.\nTo date, the group has invested approximately RMB27.00 million in research and development of FXS0683. According to IQVIA CHPA data, China’s Bcl-2 inhibitor market generated sales of roughly RMB338.00 million in 2025, underscoring the commercial potential of novel entrants in this therapeutic class.\nThe investigational drug must still progress through the full clinical trial pathway and obtain further regulatory approvals before commercialization. The company cautions that drug development carries inherent uncertainties, including potential termination of trials due to safety or efficacy concerns.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183078618","isCrawlerRequest":true}